PsiOxus Lands $34M to Create 4 Years of Runway for ColoAd1
LONDON – PsiOxus Therapeutics Ltd. has raised £22 million (US$34 million) in its Series B round to finance the first clinical trial of its systemically acting oncolytic virus ColoAd1, in a 132-patient colorectal cancer study that will get under way in September.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST